The short answer
Semaglutide patent protection expired in Canada on 4 January 2026 and in India, Brazil and China in March 2026. Reporting indicates multiple manufacturers launched generics in India within days, several at 70 to 90 per cent below the innovator price.
Key facts
- Canada
- Expired 4 January 2026 (first G7 nation)
- India, Brazil, China
- March 2026
- Canadian filers reported
- Sandoz, Apotex, Teva, Aspen
- India, reported discounts
- 70-90% below innovator
- India brand count
- 40+ reported by end of April
- Wave 1 markets
- Eight, including Mexico and Turkey
- UK and US
- Not in this wave
Why patents expire at different times in different countries
Patents are national. A molecule protected in one jurisdiction may be unprotected in another, depending on when and where applications were filed, what term extensions were granted, and whether secondary patents on formulation or use were upheld. A single compound therefore goes off patent in a staggered sequence rather than everywhere at once.
What happened in Canada
Reporting indicates the main protection lapsed on 4 January 2026, making Canada the first G7 country where this occurred, with filings from several established generic manufacturers following. Canada is a substantial market and the first major-economy test of what generic entry does to this class.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What happened in India
Expiry is reported as 20 March 2026, followed within days by launches from several domestic manufacturers, with brand counts reported above 40 by the end of April and prices reported at 70 to 90 per cent below the innovator. India has substantial domestic generic manufacturing capacity, which is why entry there is fast and crowded rather than gradual.
Why the entry is so rapid
Because semaglutide is regulated as a drug rather than a biologic. At 31 amino acids it sits below the 40-residue threshold, so a generic files an abbreviated application demonstrating bioequivalence rather than running the comparative clinical programme a biosimilar requires. That difference is measured in years and in orders of magnitude of cost.
What this does not change
That semaglutide is a prescription medicine. Patent expiry alters who may lawfully manufacture and sell it; it does not alter its regulatory status, the requirement for a prescription, or the standards a product must meet. Off-patent is not the same as unrestricted, and it is the word most likely to be misread that way.
The UK position
The United Kingdom is not in this first wave. UK protection and availability follow their own timeline, and separately from any patent question, NHS funding is determined by NICE rather than by whether a generic exists.
And what it has to do with research material
Nothing. A generic semaglutide is a licensed medicine made by a different company. It does not become a research chemical, and nothing supplied on this site is semaglutide, generic or otherwise, or an alternative to it.
Frequently asked questions
When did semaglutide go off patent?
Reported as 4 January 2026 in Canada (the first G7 nation) and March 2026 in India, Brazil and China.
Why did generics appear so quickly?
Semaglutide is 31 amino acids, below the 40-residue threshold, so it is regulated as a drug and generics file for bioequivalence rather than as biosimilars.
Does off-patent mean available without prescription?
No. Patent expiry changes who may manufacture it, not its regulatory status or the requirement for a prescription.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Two Pathways, Two TimescalesA generic drug shows bioequivalence. A biosimilar shows no clinically meaningful difference. The 40-residue line decides which applies.
- Comparing an Operation With an InjectionA 2026 network meta-analysis compared metabolic and bariatric surgery against GLP-1 receptor agonists. Why the comparison is harder than it looks.
- Does Amylin Need a GLP-1 Partner?CagriSema pairs amylin with semaglutide and missed non-inferiority. A 2026 review surveys long-acting amylin peptides being developed on their own.
- The Trial Where Glucose-Dependence Shows Up in Numbers2,002 randomised, 52 weeks. Hypoglycaemia 6-9% with tirzepatide against 19% with glargine - and 1-3% versus 16% without a sulfonylurea.
- TRIUMPH-4: The First Retatrutide Phase 3 to Read OutTRIUMPH-4 randomised 445 adults with obesity and knee osteoarthritis. Co-primary endpoints, two estimands, and a pain result that did not track the dose.